...in Tango, expands 2018 dealGilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango... ...immuno-oncology targets in exchange for $125 million up front and a $20 million equity investment. Tango... ...double-digit tiered royalties. Tango may co-promote and co-develop up to five programs in the U.S. (see “Tango...
...Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally... ...advanced programs are generally among Tango’s oldest ones; others may create opportunities for business development. Tango... ...exceeds $1.7 billion (see “Tango, Gilead Partner” ). The deal’s upfront payment, which nearly matched Tango’s...
...for the antibiotic Xerava eravacycline. Medivir enters preclinical cancer deal with Tango Synthetic lethality company Tango... ...for undisclosed upfront and development and commercial milestone payments as well as low single-digit royalties. Tango... ...TP-434)
teplizumab (MGA031, PRV-031)
Viaskin Peanut (DBV-712)
Novo Nordisk A/S
Merz GmbH & Co. KGaA
Zai Lab Ltd.
...developing a POLQ inhibitor and expects to enter the clinic by 2021. Both Repare and Tango... ...Tango Therapeutics Inc., Cambridge, Mass.
Elizabeth S. Eaton, Staff Writer
Artios Pharma Ltd.
Cancer Research UK
Repare Therapeutics Inc.